ClinicalTrials.gg
CompletedNCT03245151Updated Aug 30, 2023Results posted

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

A Phase 1/2 interventional study of Lenvatinib and Everolimus in Recurrent and Refractory Solid Tumors, sponsored by Eisai Inc.. Completed at 50 sites in 2 countries. Open to participants aged 2 Years to 21 Years. Per ClinicalTrials.gov, last updated 2023-08-30.

Primary conditionCentral Nervous System NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Central Nervous System Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's title name Central Nervous System Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eisai Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
2 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 547 studies in Central Nervous System Neoplasms with a site in United States — 46 open to participants now, 74 under way, 3 of them phase 3. Central Nervous System Neoplasms · United States.

Enrollment
106th of 399
64 · median 31
Started
2017
with 21 others
Phase 1/2
70 of 547
7 open now
Registered
448th of 547
by date

Among the 547 studies in Central Nervous System Neoplasms with a site in United States, this one is the 106th largest by enrollment of the 399 interventional ones that give a count, is one of 22 that started in 2017, is one of 70 in phase 1/2, and was the 448th registered.

Central Nervous System Neoplasms

699 studies on the registry are indexed under Central Nervous System Neoplasms; 66 are open to participants now.

Browse Central Nervous System Neoplasms studies →

Open to participants now

46 of the 547 studies in Central Nervous System Neoplasms with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Central Nervous System Neoplasms studies recruiting now, 35 (61%) set no upper age limit and 19 (33%) stop at 75 or younger; 35 take children under 18; 6 take healthy volunteers.

This study: 2 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Central Nervous System Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with everolimus once daily to pediatric participants with recurrent/refractory solid tumors. Phase 2, utilizing Simon's optimal 2-stage design, will be conducted to estimate the antitumor activity of lenvatinib in combination with everolimus in pediatric participants with selected recurrent/refractory solid tumors including Ewing sarcoma, rhabdomyosarcoma, and high grade glioma (HGG) using objective response rate (ORR) at Week 16 as the outcome measure.

03

Conditions studied

  • Recurrent and Refractory Solid Tumors

Keywords

  • pediatrics
  • central nervous system tumors
  • lenvatinib
  • E7080
  • everolimus
  • Ewing sarcoma/peripheral primitive neuroectodermal tumor
  • rhabdomyosarcoma
  • high grade glioma
  • solid tumors
04

In context

Central Nervous System Neoplasms Reclassified

699 studies on the registry are indexed under Central Nervous System Neoplasms; 66 are open to participants now.

This study's enrollment of 64 is above the median of 35 across 487 interventional studies indexed under Central Nervous System Neoplasms.

Browse Central Nervous System Neoplasms studies →

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Compared within Central Nervous System Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥2 years and \<18 years of age for enrolment in Phase 1 or ≥2 years and ≤21 years of age for enrolment in Phase 2.
  • Recurrent or solid tumors

    • Phase 1: All solid tumors (measurable or evaluable disease), including primary central nervous system (CNS) tumors; exclusion of hepatoblastoma and lymphomas. Participants with diffuse intrinsic pontine glioma, optic pathway glioma, or pineal tumors with elevated tumor markers (alpha-fetoprotein [AFP] and beta-human chorionic gonadotropin [ß-hCG][or human chorionic gonadotropin [hCG])do not require histological or cytological confirmation of diagnosis
    • Phase 2: Ewing sarcoma, Rhabdomyosarcoma, High Grade Glioma (HGG) (all must have ); exclusion of Diffuse Intrinsic Pontine Glioma
  • or cytologically confirmed diagnosis
  • Measurable disease that meets the following criteria (Phase 2):

    1. 1.1 (for all tumor types except HGG): At least 1 lesion of ≥1.0 cm in the longest diameter for a non lymph node or ≥1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computed tomography /magnetic resonance imaging (CT/MRI)
    2. Response Assessment in Neuro-Oncology (RANO) for high grade glioma (HGG): At least one lesion must be measurable as defined as a bi dimensionally contrast enhancing lesion with clearly defined margins by CT or MRI scan, with a minimal diameter of 1 cm, and visible on 2 axial slices which are preferably at most 5 mm apart with 0 mm skip

Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion

  • performance score ≥50 for participants>16 year of age and Lansky play score ≥50 for participants ≤16 years of age. Neurologic deficits in participants with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
  • Prior Therapy

    • Participants must have fully recovered from the acute toxic effects of all prior anti-cancer therapy
    • Cytotoxic chemotherapy or other chemotherapy known to be myelosuppressive: ≥21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
    • Anti-cancer agents not known to be myelosuppressive (eg, not associated with reduced or ): ≥7 days after the last dose of agent
    • Monoclonal antibodies: ≥21 days or 3 half-lives (whichever is shorter) of the antibody must have elapsed after the last dose of a monoclonal antibody (including ). Toxicity related to prior antibody therapy must be recovered to Grade ≤1
    • : If used to modify immune adverse events related to prior therapy, ≥14 days must have elapsed since last dose of corticosteroid. Participants receiving corticosteroids, who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment, are not eligible
    • Hematopoietic growth factors: ≥14 days after the last dose of a long-acting growth factor or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur
    • Interleukins, interferons, and cytokines (other than hematopoietic growth factors): ≥21 days after the completion of interleukins, interferons or cytokines (other than hematopoietic growth factors)
    • Stem cell infusions (with or without total body irradiation): Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocytes infusion or boost infusion: ≥84 days after infusion and no evidence of ; Autologous stem cell infusion including boost infusion: ≥42 days
    • Cellular Therapy: ≥42 days after the completion of any type of cellular therapy (eg, modified T cells, natural killer cells, dendritic cells, etc)
    • Radiotherapy (XRT)/External Beam Irradiation including Protons: ≥14 days after local XRT; ≥150 days after total body irradiation, craniospinal XRT or if radiation to ≥50% of the pelvis; ≥42 days if other substantial bone marrow radiation.
    • Radiopharmaceutical therapy: ≥42 days after systemically administered therapy.
    • Vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-targeted or mammalian target of rapamycin (mTOR)-targeted therapies: Must not have received prior exposure to lenvatinib; May have previously progressed on an mTOR inhibitor; No more than 2 prior VEGF/VEGFR-targeted therapies (For Phase 2 only); Must not have received prior VEGF/VEGFR-targeted therapy in combination with an mTOR inhibitor (For Phase 2 only)
  • Adequate bone marrow function for participants with solid tumors without known bone marrow involvement
  • Adequate bone marrow function for participants with known bone marrow disease
  • Adequate renal function
  • Adequate liver function
  • Adequate cardiac function
  • Adequate neurologic function
  • Adequate blood pressure (BP) control with or without antihypertensive medications
  • Adequate coagulation
  • Adequate pancreatic function
  • Adequate metabolic function
  • Adequate glycemic control
  • Participants must have a minimum body surface area (BSA) of 0.6 m\^2 at study entry.

Exclusion criteria

Exclusion Criteria

  • Participants who have had or are planning to have the following invasive procedures

    • Major surgical procedure, laparoscopic procedure, open or significant traumatic injury within 28 days prior to enrolment
    • Central line placement or subcutaneous port placement is not considered major surgery. External central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment
    • Fine needle aspirate within 7 days prior to enrolment
    • Surgical or other wounds must be adequately healed prior to enrolment
    • For purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy
  • Participants who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrolment
  • Participants having an active infection requiring systemic therapy.
  • Participants with a known history of active (defined as hepatitis B surface antigen reactive or hepatitis B virus- deoxyribonucleic [DNA] detected) or known active virus (HCV, defined as HCV- Ribonucleic acid [RNA] detected). Note: No testing for hepatitis B and hepatitis C is required unless mandated by the local health authority.
  • Known to be (HIV) positive. Note: HIV testing is required at screening only when mandated by the local health authority
  • Clinical evidence of nephrotic syndrome prior to enrolment
  • Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within 21 days prior to enrolment
  • Thrombotic/ thromboembolic event requiring systemic anticoagulation within 90 days prior to enrollment
  • Evidence of new intracranial hemorrhage of more than punctate size on MRI assessment obtained within 28 days prior to study enrollment for Participants with HGG
  • Diagnosis of lymphoma
  • Radiographic evidence of major blood vessel invasion/infiltration.
  • Evidence of untreated (exception: participants with primary CNS tumors and )
  • Participants who are currently receiving enzyme-inducing anticonvulsants
  • Participants chronically receiving strong cytochrome P450 3A4 ()/P-glycoprotein (P-gp) inhibitors or inducers within 7 days prior to study enrollment
  • Females who are breastfeeding or pregnant. For females of , a negative screening pregnancy test must be obtained within 72 hours before the first dose of study drug
  • Males who have not had a successful vasectomy (confirmed azoospermia) or if they and their female partners do not meet the criteria above (that is, not of childbearing potential or practicing highly effective throughout the study period and for 7 days after lenvatinib discontinuation or 4 weeks after discontinuation of everolimus). No sperm donation is allowed during the study period and for 7 days after lenvatinib discontinuation or 4 weeks after discontinuation of everolimus.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Phase 1: Phase 1; Recurrent or refractory solid tumors

    During Phase 1 (Treatment Phase: 1 cycle; 28 days of treatment), utilizing a rolling 6 design, participants with recurrent or refractory solid tumors will receive escalating doses of lenvatinib in combination with everolimus for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Participants who complete 1 cycle of treatment will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.

    Drug: Lenvatinib · Drug: Everolimus

  • Experimental
    Phase 2: Cohort 1, Ewing sarcoma

    During Phase 2 (four 28-day cycles \[up to 16 weeks of treatment\]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory Ewing sarcoma (Cohort 1) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1. Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.

    Drug: Lenvatinib · Drug: Everolimus

  • Experimental
    Phase 2: Cohort 2, Rhabdomyosarcoma

    During Phase 2 (four 28-day cycles \[up to 16 weeks of treatment\]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory rhabdomyosarcoma (Cohort 2) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks of treatment). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.

    Drug: Lenvatinib · Drug: Everolimus

  • Experimental
    Phase 2: Cohort 3, High Grade Glioma (HGG)

    During Phase 2 (four 28-day cycles \[up to 16 weeks of treatment\]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory HGG (Cohort 3) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.

    Drug: Lenvatinib · Drug: Everolimus

Interventions

  • oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension

  • 2 mg, 3 mg, or 5 mg tablets for oral suspension

07

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus

    MTD was defined as the highest dose level at which no more than 1/6 participants experienced a dose limiting toxicity (DLTs), with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. DLT was graded according to common terminology criteria for adverse events (CTCAE) version 4.03.

    Time frame: Cycle 1 (Each cycle was of 28 days)

  2. Phase 1: Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Everolimus

    The RP2D of lenvatinib in combination with everolimus was determined by Dose Escalation Committee (DEC) based on safety (including DLTs), pharmacokinetic and clinical data. DLT was graded according to CTCAE v4.03.

    Time frame: Cycle 1 (Each cycle was of 28 days)

  3. Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    A TEAE was defined as an adverse event that emerged during treatment, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event is continuous. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.

    Time frame: From date of first dose up to 28 days after the last dose of study treatment (Up to 17.5 months)

  4. Phase 1: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)

    A TESAE was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the above mentioned criteria. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.

    Time frame: From date of first dose up to 28 days after the last dose of study treatment (Up to 17.5 months)

  5. Phase 2: Objective Response Rate (ORR) at Week 16

    ORR at Week 16 was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) at Week 16 based on investigator assessment according to response evaluation criteria in solid tumors (RECIST) version 1.1 for non-HGG cohorts and response assessment in neuro-oncology (RANO) for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis less than (\<) 10 millimeter (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters.

    Time frame: Week 16

Secondary outcomes

  1. Phase 1: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with BOR of CR or PR based on investigator assessment according to RECIST version 1.1 for non-HGG cohorts and RANO for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of the first dose of study drug to the date of first documentation of disease progression or death, whichever occurred first (up to 16.5 months)

  2. Phase 2: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with BOR of CR or PR based on investigator assessment according to RECIST version 1.1 for non-HGG cohorts and RANO for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of the first dose of study drug to the date of first documentation of disease progression or death, which ever occurred first (up to 6.5 months)

  3. Phase 1: Disease Control Rate (DCR)

    DCR was defined as percentage of participants with a confirmed CR, PR, or stable disease (SD) (SD duration \>=7 weeks since the first dose of study treatment) divided by number of participants in analysis set. DCR was assessed by an investigator based on RECIST v1.1 for non-HGG participants or RANO for HGG participants. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: From first dose of study drug until PD or death, whichever occurred first (up to 16.5 months)

  4. Phase 2: Disease Control Rate (DCR)

    DCR was defined as percentage of participants with confirmed CR, PR, or SD (SD duration greater than or equal to \[\>=\] 7 weeks since first dose of study treatment) divided by number of participants in analysis set. DCR was assessed by investigator based on RECIST v1.1 for non-HGG cohorts or RANO for HGG cohort. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: From first dose of study drug until PD or death, whichever occurred first (up to 6.5 months)

  5. Phase 1: Clinical Benefit Rate (CBR)

    CBR was defined as percentage of participants who had BOR of CR, PR, or durable SD (SD duration \>=23 weeks since the first dose of study treatment) divided by number of participants in analysis set. CBR was assessed by an investigator based on RECIST v1.1 for non-HGG participants or RANO for HGG participants. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: From first dose of study drug until PD or death, whichever occurred first (up to 16.5 months)

  6. Phase 2: Clinical Benefit Rate (CBR)

    CBR was defined as percentage of participants who had BOR of CR, PR, or durable SD (SD duration \>=23 weeks since the first dose of study treatment) divided by number of participants in analysis set. CBR was assessed by an investigator based on RECIST v1.1 for non-HGG cohorts or RANO for HGG cohort. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: From first dose of study drug until PD or death, whichever occurred first (up to 6.5 months)

  7. Phase 1: Duration of Response (DOR)

    DOR was defined as the time (in months) from the date of first observation of confirmed response (PR or CR) to the date of the first observation of progression based on the investigator's assessment utilizing RECIST 1.1 for non-HGG cohorts and RANO for HGG cohorts, or date of death, whatever the cause. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: From date of the first observation of CR or PR until the date of first observation of progression or date of death (up to 16.5 months)

  8. Phase 2: Duration of Response (DOR)

    DOR was defined as the time (in months) from the date of first observation of confirmed response (PR or CR) to the date of the first observation of progression based on the investigator's assessment utilizing RECIST 1.1 for non-HGG cohorts and RANO for HGG cohort, or date of death, whatever the cause. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: From date of the first observation of CR or PR until the date of first observation of progression or date of death (up to 6.5 months)

  9. Phase 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of Lenvatinib (AUC[0-t Hours])

    AUC0-t of lenvatinib was quantified using validated liquid chromatography tandem mass spectrometry (LC-MS/MS) methods.

    Time frame: Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=28 days)

  10. Phase 1: Maximum Plasma Concentration of Lenvatinib (Cmax)

    Cmax of lenvatinib was quantified using validated liquid LC-MS/MS methods.

    Time frame: Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=28 days)

  11. Phase 1: Time to Reach Maximum Plasma Concentration (Cmax) of Lenvatinib (Tmax)

    Tmax of lenvatinib was quantified using validated liquid LC-MS/MS methods.

    Time frame: Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=28 days)

  12. Phase 1: Trough Concentrations (Ctrough) of Everolimus When Administered in Combination With Lenvatinib

    Trough concentrations of everolimus was quantified using validated liquid LC-MS/MS methods.

    Time frame: Cycle 1 Days 1, 2, 15 and 22: Pre-dose (Cycle length=28 days)

  13. Phase 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    A TEAE was defined as an adverse event that emerged during treatment, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event is continuous. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.

    Time frame: From date of first dose up to 28 days after the last dose of study treatment (up to 7.5 months)

  14. Phase 2: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)

    A TESAE was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the above mentioned criteria. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.

    Time frame: From date of first dose up to 28 days after the last dose of study treatment (up to 7.5 months)

08

Results

Posted Aug 30, 2023

Participant flow

Participants took part in the study at 24 investigative sites in the United States and Canada from 16 November 2017 to 30 September 2022.

Participant flow — Overall Study
MilestonePhase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2Phase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGG
Started518102011
Completed03123
Not completed5159188
Withdrew: Withdrawal by subject20021
Withdrew: Death3149167
Withdrew: Sponsor's decision01000

Outcome measures

PrimaryPhase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus

MTD was defined as the highest dose level at which no more than 1/6 participants experienced a dose limiting toxicity (DLTs), with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. DLT was graded according to common terminology criteria for adverse events (CTCAE) version 4.03.

Time frame:
Cycle 1 (Each cycle was of 28 days)
Reported as:
Number · milligram per square meter (mg/m^2)
Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus
milligram per square meter (mg/m^2)Phase 1: Lenvatinib + Everolimus (All Participants)
Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus11
PrimaryPhase 1: Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Everolimus

The RP2D of lenvatinib in combination with everolimus was determined by Dose Escalation Committee (DEC) based on safety (including DLTs), pharmacokinetic and clinical data. DLT was graded according to CTCAE v4.03.

Time frame:
Cycle 1 (Each cycle was of 28 days)
Reported as:
Number · mg/m^2
Phase 1: Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Everolimus
mg/m^2Phase 1: Lenvatinib + Everolimus (All Participants)
Phase 1: Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Everolimus11
PrimaryPhase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

A TEAE was defined as an adverse event that emerged during treatment, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event is continuous. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.

Time frame:
From date of first dose up to 28 days after the last dose of study treatment (Up to 17.5 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsPhase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2
Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)518
PrimaryPhase 1: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)

A TESAE was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the above mentioned criteria. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.

Time frame:
From date of first dose up to 28 days after the last dose of study treatment (Up to 17.5 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)
ParticipantsPhase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2
Phase 1: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)212
PrimaryPhase 2: Objective Response Rate (ORR) at Week 16

ORR at Week 16 was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) at Week 16 based on investigator assessment according to response evaluation criteria in solid tumors (RECIST) version 1.1 for non-HGG cohorts and response assessment in neuro-oncology (RANO) for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis less than (\<) 10 millimeter (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Phase 2: Objective Response Rate (ORR) at Week 16
percentage of participantsPhase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGG
Phase 2: Objective Response Rate (ORR) at Week 160.0 ± 0.010.0 ± 1.20 ± 0.0
SecondaryPhase 1: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with BOR of CR or PR based on investigator assessment according to RECIST version 1.1 for non-HGG cohorts and RANO for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of the first dose of study drug to the date of first documentation of disease progression or death, whichever occurred first (up to 16.5 months)
Reported as:
Number · percentage of participants
Phase 1: Objective Response Rate (ORR)
percentage of participantsPhase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2
Phase 1: Objective Response Rate (ORR)0.0 ± 0.00.0 ± 0.0
SecondaryPhase 2: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with BOR of CR or PR based on investigator assessment according to RECIST version 1.1 for non-HGG cohorts and RANO for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of the first dose of study drug to the date of first documentation of disease progression or death, which ever occurred first (up to 6.5 months)
Reported as:
Number · percentage of participants
Phase 2: Objective Response Rate (ORR)
percentage of participantsPhase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGG
Phase 2: Objective Response Rate (ORR)0.0 ± 0.010.0 ± 1.20.0 ± 0.0
SecondaryPhase 1: Disease Control Rate (DCR)

DCR was defined as percentage of participants with a confirmed CR, PR, or stable disease (SD) (SD duration \>=7 weeks since the first dose of study treatment) divided by number of participants in analysis set. DCR was assessed by an investigator based on RECIST v1.1 for non-HGG participants or RANO for HGG participants. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
From first dose of study drug until PD or death, whichever occurred first (up to 16.5 months)
Reported as:
Number · percentage of participants
Phase 1: Disease Control Rate (DCR)
percentage of participantsPhase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2
Phase 1: Disease Control Rate (DCR)20.0 ± 0.550.0 ± 26.0
SecondaryPhase 2: Disease Control Rate (DCR)

DCR was defined as percentage of participants with confirmed CR, PR, or SD (SD duration greater than or equal to \[\>=\] 7 weeks since first dose of study treatment) divided by number of participants in analysis set. DCR was assessed by investigator based on RECIST v1.1 for non-HGG cohorts or RANO for HGG cohort. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
From first dose of study drug until PD or death, whichever occurred first (up to 6.5 months)
Reported as:
Number · percentage of participants
Phase 2: Disease Control Rate (DCR)
percentage of participantsPhase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGG
Phase 2: Disease Control Rate (DCR)40.0 ± 12.240.0 ± 19.130.0 ± 6.7
SecondaryPhase 1: Clinical Benefit Rate (CBR)

CBR was defined as percentage of participants who had BOR of CR, PR, or durable SD (SD duration \>=23 weeks since the first dose of study treatment) divided by number of participants in analysis set. CBR was assessed by an investigator based on RECIST v1.1 for non-HGG participants or RANO for HGG participants. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
From first dose of study drug until PD or death, whichever occurred first (up to 16.5 months)
Reported as:
Number · percentage of participants
Phase 1: Clinical Benefit Rate (CBR)
percentage of participantsPhase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2
Phase 1: Clinical Benefit Rate (CBR)20.0 ± 0.522.2 ± 6.4
SecondaryPhase 2: Clinical Benefit Rate (CBR)

CBR was defined as percentage of participants who had BOR of CR, PR, or durable SD (SD duration \>=23 weeks since the first dose of study treatment) divided by number of participants in analysis set. CBR was assessed by an investigator based on RECIST v1.1 for non-HGG cohorts or RANO for HGG cohort. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
From first dose of study drug until PD or death, whichever occurred first (up to 6.5 months)
Reported as:
Number · percentage of participants
Phase 2: Clinical Benefit Rate (CBR)
percentage of participantsPhase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGG
Phase 2: Clinical Benefit Rate (CBR)20.0 ± 2.510.0 ± 1.20.0 ± 0.0
SecondaryPhase 1: Duration of Response (DOR)

DOR was defined as the time (in months) from the date of first observation of confirmed response (PR or CR) to the date of the first observation of progression based on the investigator's assessment utilizing RECIST 1.1 for non-HGG cohorts and RANO for HGG cohorts, or date of death, whatever the cause. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
From date of the first observation of CR or PR until the date of first observation of progression or date of death (up to 16.5 months)

No measurements were reported for this outcome.

SecondaryPhase 2: Duration of Response (DOR)

DOR was defined as the time (in months) from the date of first observation of confirmed response (PR or CR) to the date of the first observation of progression based on the investigator's assessment utilizing RECIST 1.1 for non-HGG cohorts and RANO for HGG cohort, or date of death, whatever the cause. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
From date of the first observation of CR or PR until the date of first observation of progression or date of death (up to 6.5 months)
Reported as:
Median · months
Phase 2: Duration of Response (DOR)
monthsPhase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGG
Phase 2: Duration of Response (DOR)—2.4 (2.1 to NA)—
SecondaryPhase 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of Lenvatinib (AUC[0-t Hours])

AUC0-t of lenvatinib was quantified using validated liquid chromatography tandem mass spectrometry (LC-MS/MS) methods.

Time frame:
Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=28 days)
Reported as:
Mean · nanogram*hour per milliliter (ng*hr/mL)
Phase 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of Lenvatinib (AUC[0-t Hours])
nanogram*hour per milliliter (ng*hr/mL)Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2
Cycle 1 Day 12338.0 ± 1633.413281.1 ± 1064.72
Cycle 1 Day 151328.0 ± 520.692139.8 ± 1156.48
SecondaryPhase 1: Maximum Plasma Concentration of Lenvatinib (Cmax)

Cmax of lenvatinib was quantified using validated liquid LC-MS/MS methods.

Time frame:
Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=28 days)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Phase 1: Maximum Plasma Concentration of Lenvatinib (Cmax)
nanogram per milliliter (ng/mL)Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2
Cycle 1 Day 1240.20 ± 130.892404.13 ± 121.473
Cycle 1 Day 15314.20 ± 149.527447.62 ± 272.790
SecondaryPhase 1: Time to Reach Maximum Plasma Concentration (Cmax) of Lenvatinib (Tmax)

Tmax of lenvatinib was quantified using validated liquid LC-MS/MS methods.

Time frame:
Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=28 days)
Reported as:
Median · hours
Phase 1: Time to Reach Maximum Plasma Concentration (Cmax) of Lenvatinib (Tmax)
hoursPhase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2
Cycle 1 Day 13.000 (2.000 to 4.000)2.890 (1.000 to 7.78)
Cycle 1 Day 153.950 (2.000 to 8.05)2.950 (0 to 8.02)
SecondaryPhase 1: Trough Concentrations (Ctrough) of Everolimus When Administered in Combination With Lenvatinib

Trough concentrations of everolimus was quantified using validated liquid LC-MS/MS methods.

Time frame:
Cycle 1 Days 1, 2, 15 and 22: Pre-dose (Cycle length=28 days)
Reported as:
Mean · ng/mL
Phase 1: Trough Concentrations (Ctrough) of Everolimus When Administered in Combination With Lenvatinib
ng/mLPhase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2
Cycle 1 Day 1: Pre-dose0.0 ± 0.00.0 ± 0.00
Cycle 1 Day 2: Pre-dose2.1 ± 1.342.2 ± 1.13
Cycle 1 Day 15: Pre-dose3.2 ± 2.425.1 ± 2.98
Cycle 1 Day 22: Pre-dose2.8 ± 1.964.2 ± 2.73
SecondaryPhase 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

A TEAE was defined as an adverse event that emerged during treatment, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event is continuous. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.

Time frame:
From date of first dose up to 28 days after the last dose of study treatment (up to 7.5 months)
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsPhase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGG
Phase 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)101911
SecondaryPhase 2: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)

A TESAE was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the above mentioned criteria. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.

Time frame:
From date of first dose up to 28 days after the last dose of study treatment (up to 7.5 months)
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)
ParticipantsPhase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGG
Phase 2: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)688

Adverse events

Collected over From date of first dose up to 28 days after the last dose of study treatment (Phase 1: Up to 17.5 months; Phase 2: Up to 7.5 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^24/5 (80%)2/5 (40%)5/5 (100%)
Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^214/18 (77.8%)12/18 (66.7%)18/18 (100%)
Phase 2: Cohort 1, Ewing Sarcoma9/10 (90%)6/10 (60%)10/10 (100%)
Phase 2: Cohort 2, Rhabdomyosarcoma17/20 (85%)8/20 (40%)19/20 (95%)
Phase 2: Cohort 3, HGG8/11 (72.7%)8/11 (72.7%)11/11 (100%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventPhase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2Phase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGG
PyrexiaGeneral disorders0/50/183/101/200/11
PainGeneral disorders1/52/180/101/200/11
HeadacheNervous system disorders1/51/180/100/201/11
Pleural effusionRespiratory, thoracic and mediastinal disorders0/50/182/101/200/11
SeizureNervous system disorders0/53/180/100/202/11
HypoxiaRespiratory, thoracic and mediastinal disorders0/53/181/101/200/11
Back painMusculoskeletal and connective tissue disorders0/52/180/100/200/11
SepsisInfections and infestations0/50/181/100/200/11
Upper respiratory tract infectionsInfections and infestations0/50/180/102/200/11
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/50/181/100/200/11
Most frequent other events
Showing 10 of 199
Most frequent other events
EventPhase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2Phase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGG
NauseaGastrointestinal disorders4/55/183/109/204/11
StomatitisGastrointestinal disorders4/55/182/109/202/11
Lymphocyte count decreasedInvestigations3/56/188/1011/202/11
Decreased appetiteMetabolism and nutrition disorders4/54/182/106/202/11
HypophosphataemiaMetabolism and nutrition disorders1/53/188/106/201/11
Back painMusculoskeletal and connective tissue disorders4/51/181/104/202/11
ProteinuriaRenal and urinary disorders1/58/188/1010/204/11
HypertensionVascular disorders4/513/183/1010/204/11
HyponatraemiaMetabolism and nutrition disorders1/56/187/102/201/11
DiarrhoeaGastrointestinal disorders3/510/185/108/207/11

Baseline characteristics

Safety Analysis Set (SAS) included all participants who received at least 1 dose of study drug (lenvatinib or everolimus).

Age, Customized
Age, Customized(Participants)Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2Phase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGGTotal
2-11 years01639331
12-17 years4136721
18-64 years1145112
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2Phase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGGTotal
Female21038831
Male38712333
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2Phase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGGTotal
Hispanic or Latino1722012
Not Hispanic or Latino4118181152
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2Phase 2: Cohort 1, Ewing SarcomaPhase 2: Cohort 2, RhabdomyosarcomaPhase 2: Cohort 3, HGGTotal
American Indian or Alaska Native010001
Asian011002
Native Hawaiian or Other Pacific Islander000000
Black or African American110136
White311916645
More than one race000000
Unknown or Not Reported1403210
09

Study locations

50 sites
  • Children's Hospital of Alabama
    Birmingham, Alabama 35233, United States
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92350, United States
  • Miller Children's and Women's Hospital
    Long Beach, California 90806, United States
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • Southern California Permanente Medical Group
    Los Angeles, California 90027, United States
  • Kaiser Permenente
    Oakland, California 94611, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • UCSF Medical Center at Mission Bay - Pediatric Oncology
    San Francisco, California 94158, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Nemours/ Alfred I. duPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Golisano Children's Hospital of Southwest Florida
    Fort Myers, Florida 33908, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • Kapi'olani Medical Center
    Honolulu, Hawaii 96826, United States
  • St Jude Midwest Affiliate
    Peoria, Illinois 61637, United States
  • Riley Hospital for Children - Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Louisville and Norton Children's Hospital
    Louisville, Kentucky 40202, United States
  • Johns Hopkins
    Baltimore, Maryland 21287, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • CS Mott Children's Hospital
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota/Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Children's Mercy Hospital and Clinics
    Kansas City, Missouri 64108, United States
  • Alliance for Childhood Diseases
    Las Vegas, Nevada 89135, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Rutgers cancer Institute of NJ
    New Brunswick, New Jersey 08901, United States
  • Cohen Children's Medical Center
    New Hyde Park, New York 11040, United States
  • Columbia University/Herbert Irving Cancer Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Dell Children's Medical Center of Central Texas
    Austin, Texas 78723, United States
  • The University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • The Children's Hospital of San Antonio
    San Antonio, Texas 78207, United States
  • Children's Hospital of The King's Daughters
    Norfolk, Virginia 23507, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • IWK Health Centre
    Halifax, Nova Scotia B3K 6R8, Canada
  • Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Montreal Children's Hospital
    Montreal, Quebec H4A3J1, Canada
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Sep 2022, 58 months.

Results were first posted in Aug 2023, 11 months after primary completion.

Of 35 phase 1/2 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 85. This study's 58 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2017
First posted
Aug 10, 2017
StartActual
Nov 16, 2017
Primary completionActual
Sep 30, 2022
CompletionActual
Sep 30, 2022
Results first posted
Aug 30, 2023
Last update
Aug 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03245151
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Aug 10, 2017
Start date
Nov 16, 2017
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022
Results posted
Aug 30, 2023
Last update
Aug 30, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion